Cases & Deals

  • Home
  • Practices
  • Baxter International obtains antitrust clearance from FTC to sell injectable pharmaceuticals business to Hikma

Share

Baxter International obtains antitrust clearance from FTC to sell injectable pharmaceuticals business to Hikma

April 2011

Client(s) Baxter International Inc.

Jones Day represented Baxter International Inc. as antitrust counsel in connection with the sale of Baxter's injectable pharmaceuticals business to Hikma Pharmaceuticals PLC. Baxter's generic injectable products in vials and ampoules are sold primarily in the United States, and include chronic pain, anti-infective, and anti-emetic products. The Federal Trade Commission cleared the transaction following a comprehensive investigation and entry of a consent agreement with Hikma.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.